Myelodysplastic Syndrome

What are the management option in low risk MDS patients with isolated anemia and then EPO of more than 500 milliunits/mL? Biomarker driven therapy/hypomethylating/lenalidomide agent/decitabine+cedazuridine

en_USEnglish